Lipid status in transgender patients receiving hormone affirming therapy for 6 months
Abstract
Introduction: The term “transgender” refers to a person whose sex assigned at birth does not match their gender identity. Tanssexualism can be diagnosed in all ages, aldo first sines can be seen in early childhood. This condition is treated with cross-sex hormone therapy (CSHT) and surgical reconstructions with the goal of maching the physical sex with the one that the person identifies with.
Aim: To study effects of cross-sec hormone therapy with testosterone on anthropometric characteristics, lipid and hormone status in female to male(FtM) transgenders.
Material and methods: Study includes 31 FtM patients with gender identity disorder. Beginning of CSHT was at age 26.03 ± 5.21. Patients were treated on Clinic of endocrinology, diabetes and disease of metabolism, Clinical center of Serbia. Lipid and hormone status before and during therapy were analyzed.
Results: BMI has increased significantly. Mean levels of HDL and Lp(a) were increased significantly, and there were a significant decrease in ApoA1. There were no changes in other lipid levels. During six months of testosterone therapy levels of FSH, LH and estradiol showed a significant decrease, while testosterone has increased significantly. We found higher values of RBC and hemoglobin.
Conclusion: CSHT do not lead to pathological alteration of lipid profile if dosed properly.
References
- American Psychiatric Associtation. Diagnostic and Statistical Manual of Mental Disorders. 5th edition. Washington, DC, USA: American Psychiatric Association Press; 2013.
- Vujović S, Slijepčević D, Rakić Z, Marić J, Perović S. Polni identitet i promena pola. Beograd: BIGZ; 1993.
- Walter Meyer III, Walter O. Bockting, Peggy Cohen-Kettenis, Eli Coleman, Domenico Diceglie, Louis Gooren et all. The Harry Benjamin International Gender Dysphoria Association's Standards of Care for Gender Identity Disorders, Sixth Version. Journal of Psychology & Human Sexuality. 2002; 13:1, 1-30
- International Statistical Classification of Diseases and Related Health Problems (11th ed,; ICD-11; World Health Organization, 2020).
- Gooren LJ, Giltay EJ. Review of studies of androgen treatment
of female-to-male transsexuals: Effects and risks of administration of androgens to females. J Sex Med. 2008;5:765–76.
- Vujovic, S., Popovic, S., Sbutega-Milosevic, G., Djordjevic, M., & Gooren, L. Transsexualism in Serbia: A Twenty-Year Follow-Up Study. J Sex Med. 2009; 6(4), 1018–1023.
- Jacobeit JW, Gooren LJ, Schulte HM. Safety aspects of 36 months of administration of long-acting intramuscular testosterone undecanoate for treatment of female-to-male transgender individuals. Eur J Endocrinol. 2009;161:795- 798
- Pelusi C, Costantino A, Martelli V, et al. Effects of three different testosterone formulations in female-to-male transsexual persons. J Sex Med. 2014;11:3002-3011
- Fernandez, J. D., & Tannock, L. R. Metabolic effects of hormone therapy in transgender patients. Endocrine Practice. 2016; 22(4), 383–388.
- Elamin, M. B., Garcia, M. Z., Murad, M. H., Erwin, P. J., & Montori, V. M. Effect of sex steroid use on cardiovascular risk in transsexual individuals: a systematic review and meta-analyses. Clinical Endocrinology.2010; 72(1), 1–10.
- Ott, J., Aust, S., Promberger, R., Huber, J. C., & Kaufmann, U. Cross‐Sex Hormone Therapy Alters the Serum Lipid Profile: A Retrospective Cohort Study in 169 Transsexuals. The Journal of Sexual Medicine. 2011; 8(8), 2361–2369.
- Van Kesteren, P. J. M., Asscheman, H., Megens, J. A. J., & Gooren, L. J. G. Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clinical Endocrinology. 1997; 47(3), 337–343.
- Bazarra-Castro MA, Sievers C, Fulda S, Klotsche J, Pieper L, et al. Comorbidities in Transsexual Patients under Hormonal Treatment Compared to Age- And Gender-Matched Primary Care Comparison Groups. Reproductive Sys Sexual Disord. 2012;